Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics
ZYME Price/Volume Stats
| Current price | $8.11 | 52-week high | $13.14 |
| Prev. close | $8.55 | 52-week low | $6.01 |
| Day low | $8.09 | Volume | 881,300 |
| Day high | $8.49 | Avg. volume | 580,241 |
| 50-day MA | $10.53 | Dividend yield | N/A |
| 200-day MA | $8.84 | Market Cap | 572.31M |
ZYME Stock Price Chart Interactive Chart >
Zymeworks Inc. Common Shares (ZYME) Company Bio
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.
Latest ZYME News From Around the Web
Below are the latest news stories about ZYMEWORKS INC that investors may wish to consider to help them evaluate ZYME as an investment opportunity.
Small-Cap Sensations: 3 Stocks Predicted for Massive Growth in 2024These three small-cap stocks have massive return potential in 2024 and beyond, according to analyst forecasts and broader industry trends. |
Zymeworks Announces $50 Million Private Placement to EcoR1 CapitalProceeds expected to extend cash runway into H2 2027VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an aggregate of 5,086,521 pre-funded warrants to purchase 5,086,521 shares of common stock, $0.00001 par v |
From $10k to $100k in 5 years: 3 Small-Cap Stocks to Make a FortuneAre you looking for small-cap stocks to get rich? |
Want to Turn Spare Change Into $1,000? Buy These 3 Stocks NowThree high conviction stocks seem perfect for opportunistic investors and could quickly transform spare change into four-figure returns. |
Zymeworks Added to Nasdaq Biotechnology IndexVANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, 2023. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market th |
ZYME Price Returns
| 1-mo | -22.54% |
| 3-mo | -22.02% |
| 6-mo | 21.95% |
| 1-year | -7.21% |
| 3-year | -71.44% |
| 5-year | -52.60% |
| YTD | -21.94% |
| 2023 | 32.19% |
| 2022 | -52.04% |
| 2021 | -65.32% |
| 2020 | 3.96% |
| 2019 | 209.67% |
Continue Researching ZYME
Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...